Preface: Discovery and development of better medical countermeasures for chemical threats targeting the nervous system

TY - JOUR

T1 - Preface

T2 - Discovery and development of better medical countermeasures for chemical threats targeting the nervous system

AU - Jett, David A.

AU - Galanopoulou, Aristea S.

AU - Moshé, Solomon L.

N1 - Funding Information: ASG acknowledges grant support by NINDS RO1 NS091170, U54 NS100064, the US Department of Defense (W81XWH-13-1-0180), and research funding from the Heffer Family and the Segal Family Foundations and the Abbe Goldstein / Joshua Lurie and Laurie Marsh/ Dan Levitz families. SLM is the Charles Frost Chair in Neurosurgery and Neurology and partially funded by grants from NIH U54 NS100064 (EpiBioS4Rx), and NS43209, US Department of Defense (W81XWH-13-1-0180 and W81XWH-18-1-0612), and the Heffer Family and the Segal Family Foundations, and the Abbe Goldstein/Joshua Lurie and Laurie Marsh/Dan Levitz families. DJ is director of the National Institutes of Health Countermeasures Against Chemical Threats Program. The author has no known conflicts of interest. The views expressed in this article are those of the authors and do not reflect the official policy of the NIH, Department of Health and Human Services, or the U.S. Government. No official support or endorsement of this article by the NINDS or NIH is intended or should be inferred. ASG is co-Editor in Chief of Epilepsia Open and has received royalties for publications from Elsevier and Morgan and Claypool publishers. She has received a one time honorarium for participation in an Eisai scientific advisory board. SLM is serving as Associate Editor of Neurobiology of Disease and is on the editorial board of Brain and Development, Pediatric Neurology and Physiological Research. He receives from Elsevier an annual compensation for his work as Associate Editor in Neurobiology of Disease and royalties from 2 books he co-edited. He has received consultant's fees from UCB, Mallinckrodt and Pfizer. Funding Information: SLM is the Charles Frost Chair in Neurosurgery and Neurology and partially funded by grants from NIH U54 NS100064 (EpiBioS4Rx), and NS43209 , US Department of Defense ( W81XWH-13-1-0180 and W81XWH-18-1-0612 ), and the Heffer Family and the Segal Family Foundations, and the Abbe Goldstein/Joshua Lurie and Laurie Marsh/Dan Levitz families. Funding Information: ASG acknowledges grant support by NINDS RO1 NS091170 , U54 NS100064 , the US Department of Defense ( W81XWH-13-1-0180 ), and research funding from the Heffer Family and the Segal Family Foundations and the Abbe Goldstein / Joshua Lurie and Laurie Marsh/ Dan Levitz families .

PY - 2020/1

Y1 - 2020/1

UR - http://www.scopus.com/inward/record.url?scp=85070859668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070859668&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2019.104557

DO - 10.1016/j.nbd.2019.104557

M3 - Editorial

C2 - 31374245

AN - SCOPUS:85070859668

SN - 0969-9961

VL - 133

JO - Neurobiology of Disease

JF - Neurobiology of Disease

M1 - 104557

ER -